| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Rivastigmine Tartrate (formerly ENA-713, SDZ-ENA 713; Exelon, Exelon Patch), the tartrate salt of rivastigmine, is a potent and reversible cholinesterase inhibitor used to treat mild to moderate dementia caused by Alzheimer's or Parkinson's disease. It inhibits cholinesterase with an IC50 of 5.5 μM, and is used as a parasympathomimetic or cholinergic agent for the management of mild to moderate Alzheimer disease, Dementia, and Parkinson's Disease. Rivastigmine is a carbamate-derived reversible cholinesterase inhibitor that is selective for the central nervous system. It acts by covalently modifying a serine residue in the active site by carbamoylation, as it stabilizes or reduces the rate of decline in certain cognitive functions.
| ln Vitro |
When coupled with carbachol (10 µM), rivastigmine tartrate (ENA 713; 1 µM; 24 hours) decreased TNF-α and IL-6 produced by LPS (2.5 µg/ml) by 50% and 46%, respectively. and has little to no noticeable effect. Decreases in pro-inflammatory cytokines occur [3]. On activated cells, rivastigmine tartrate (1 µM), carbachol (10 µM), or a mix of the two medications show no harmful effects [3].
|
|---|---|
| ln Vivo |
Rivastigmine tartrate (ENA 713; 0.5-2.5 mg/kg; IP; 60 minutes before testing) aluminum-induced behavioral abnormalities were considerably and dose-dependently alleviated [4]. When administered intraperitoneally (SC) to BALB/c OlaHsd male mice 8–9 weeks old weighing 200–250 grams and suffering from acute colitis, rivastigmine (0.5, 1 mg/kg/day; SC; for 8 days) decreases IL-6 concentrations by around 50% and 60%, respectively, but does not affect TNF-α. In contrast to 0.5 mg/kg, rivastigmine (1 mg/kg) totally stopped bleeding and very slightly inhibited colonic contractions. Little changed in these pathological findings after treatment with rivastigmine (0.5 mg/kg); however, rivastigmine (1 mg/kg) reduced submucosal edema and cellular infiltration and partially restored the crypt architecture. At the conclusion of the experiment, 4.7% of the participants lost weight when using rivastigmine (1 mg/kg) [3].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar albino rat, body weight 190–240 g (90 days old) [4]
Doses: 0.5, 1, 1.5 and 2.5 mg/kg Route of Administration: intraperitoneal (ip) injection; single dose Experimental Results: significant and dose Dependently improves aluminum-induced behavioral disturbances (100 mg/kg/day; i.p.; for 60 days) |
| References |
|
| Additional Infomation |
Rivastigmine tartrate is a tartrate salt obtained by reaction of rivastigmine with one equivalent of (R,R)-tartaric acid. A reversible cholinesterase inhibitor. It has a role as a cholinergic drug, an EC 3.1.1.8 (cholinesterase) inhibitor and a neuroprotective agent. It contains a rivastigmine(1+).
Rivastigmine Tartrate is the tartrate salt form of rivastigmine, a phenylcarbamate derivative exhibiting cognitive stimulating property. Although the mechanism of action has not been fully elucidated, rivastigmine tartrate may bind reversibly to cholinesterase, thereby decreasing the breakdown of acetylcholine and enhancing cholinergic function. A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE. See also: Rivastigmine (broader). Drug Indication Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. |
| Molecular Formula |
C14H22N2O2.C4H6O6
|
|
|---|---|---|
| Molecular Weight |
400.42
|
|
| Exact Mass |
400.184
|
|
| CAS # |
129101-54-8
|
|
| Related CAS # |
(S)-Rivastigmine-d6 tartrate;194930-00-2;Rivastigmine;123441-03-2
|
|
| PubChem CID |
6918078
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
316.2ºC at 760 mmHg
|
|
| Melting Point |
123-1250C
|
|
| Flash Point |
145ºC
|
|
| Vapour Pressure |
0.000416mmHg at 25°C
|
|
| LogP |
0.637
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
9
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
28
|
|
| Complexity |
402
|
|
| Defined Atom Stereocenter Count |
3
|
|
| SMILES |
CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
|
|
| InChi Key |
GWHQHAUAXRMMOT-MBANBULQSA-N
|
|
| InChi Code |
InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m01/s1
|
|
| Chemical Name |
(2R,3R)-2,3-dihydroxybutanedioic acid;[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (249.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4974 mL | 12.4869 mL | 24.9738 mL | |
| 5 mM | 0.4995 mL | 2.4974 mL | 4.9948 mL | |
| 10 mM | 0.2497 mL | 1.2487 mL | 2.4974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02063269 | Unknown † | Drug: Rivastigmine | Alzheimer's Disease | Seoul National University Hospital | February 2014 | Not Applicable |
| NCT02703636 | Completed Has Results | Drug: Rivastigmine Patch | Mild to Moderate Alzheimer's Disease | Novartis Pharmaceuticals | May 9, 2016 | Phase 4 |
| NCT00624663 | Completed | Drug: Rivastigmine | Rivastigmine Toxicity | Tel-Aviv Sourasky Medical Center | January 2009 | Not Applicable |
| NCT01073319 | Completed | Other: Placebo Drug: Rivastigmine |
Methamphetamine Dependence Substance Abuse Methamphetamine Abuse |
Baylor College of Medicine | July 2009 | Phase 1 |
| NCT02413554 | Completed | Drug: Rivastigmine patch | Delirium | Chung-Ang University Hosptial, Chung-Ang University College of Medicine |
April 2013 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA